WO2005068448A1 - Sulfonamides antagonising n-type calcium channels - Google Patents

Sulfonamides antagonising n-type calcium channels Download PDF

Info

Publication number
WO2005068448A1
WO2005068448A1 PCT/GB2004/003705 GB2004003705W WO2005068448A1 WO 2005068448 A1 WO2005068448 A1 WO 2005068448A1 GB 2004003705 W GB2004003705 W GB 2004003705W WO 2005068448 A1 WO2005068448 A1 WO 2005068448A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
amino
piperidine
alkenyl
carbocyclyl
Prior art date
Application number
PCT/GB2004/003705
Other languages
English (en)
French (fr)
Inventor
Fleur Radford
Rosemary Lynch
Sarah Louise Mellor
Christopher John Hobbs
Jenny Christine Gilbert
Stephen Stokes
Angela Glen
Andrea Fiumana
Nichola Jane Smith
Christopher Geoffrey Earnshaw
Lars Jacob Stray Knutsen
Original Assignee
Ionix Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0320294A external-priority patent/GB0320294D0/en
Priority claimed from GB0330044A external-priority patent/GB0330044D0/en
Application filed by Ionix Pharmaceuticals Limited filed Critical Ionix Pharmaceuticals Limited
Priority to EP04768255A priority Critical patent/EP1664010A1/de
Publication of WO2005068448A1 publication Critical patent/WO2005068448A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
PCT/GB2004/003705 2003-08-29 2004-08-31 Sulfonamides antagonising n-type calcium channels WO2005068448A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04768255A EP1664010A1 (de) 2003-08-29 2004-08-31 Sulfonamide als n-typ-calciumkanalantagonisten

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0320294A GB0320294D0 (en) 2003-08-29 2003-08-29 Chemical compounds
GB0320294.2 2003-08-29
GB0330044.9 2003-12-24
GB0330044A GB0330044D0 (en) 2003-12-24 2003-12-24 Chemical compounds

Publications (1)

Publication Number Publication Date
WO2005068448A1 true WO2005068448A1 (en) 2005-07-28

Family

ID=34796810

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/003705 WO2005068448A1 (en) 2003-08-29 2004-08-31 Sulfonamides antagonising n-type calcium channels

Country Status (2)

Country Link
EP (1) EP1664010A1 (de)
WO (1) WO2005068448A1 (de)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113542A2 (en) * 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
WO2006030211A2 (en) * 2004-09-14 2006-03-23 Vernalis (R & D) Limited Acyclic sulphonamides
WO2007125398A2 (en) * 2006-04-27 2007-11-08 Pfizer Japan Inc. : sulfonamide compounds as antagonists of the n-type calcium channel
JP2010504930A (ja) * 2006-09-29 2010-02-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換されたスルホンアミド誘導体
WO2010084050A2 (en) 2009-01-13 2010-07-29 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2010091721A1 (en) * 2009-02-11 2010-08-19 Glaxo Group Limited 3 -substituted 1-arylsulfonylpiperidine derivatives for the treatment of pain
JP2010529020A (ja) * 2007-05-31 2010-08-26 塩野義製薬株式会社 オキシイミノ化合物およびその使用
WO2010096371A3 (en) * 2009-02-18 2010-11-11 Boehringer Ingelheim International Gmbh Heterocyclic compounds which modulate the cb2 receptor
EP2305652A2 (de) 2005-12-08 2011-04-06 Novartis AG Trisubstituierte Chinazolinonderivate als Vanilloidantagonisten
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
EP2477963A1 (de) * 2009-09-18 2012-07-25 Zalicus Pharmaceuticals Ltd. Arylsulfonderivate als calciumkanalblocker
US8324249B2 (en) 2008-08-01 2012-12-04 Purdue Pharma L.P. Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
WO2012164473A1 (en) 2011-05-27 2012-12-06 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
WO2013164790A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
US8865744B1 (en) 2013-05-17 2014-10-21 Boehringer Ingelheim International Gmbh (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US9315454B2 (en) 2010-01-15 2016-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
CN105732458A (zh) * 2014-12-29 2016-07-06 成都先导药物开发有限公司 吡咯酰胺类化合物及其制备方法与用途
CN105732459A (zh) * 2014-12-29 2016-07-06 成都先导药物开发有限公司 吡咯酰胺类化合物及其制备方法与用途
WO2016107227A1 (zh) * 2014-12-29 2016-07-07 成都先导药物开发有限公司 吡咯酰胺类化合物及其制备方法与用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080928A1 (en) * 2001-04-03 2002-10-17 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080928A1 (en) * 2001-04-03 2002-10-17 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOEHLER, J. J. ET AL: "Intramolecular radical reactions in .alpha.-halomethyl substituted piperidine sulfonamides", TETRAHEDRON LETTERS , (7), 631-4 CODEN: TELEAY; ISSN: 0040-4039, 1977, XP002311574 *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113542A3 (en) * 2004-05-20 2006-03-02 Elan Pharm Inc N-cyclic sulfonamido inhibitors of gamma secretase
WO2005113542A2 (en) * 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
WO2006030211A2 (en) * 2004-09-14 2006-03-23 Vernalis (R & D) Limited Acyclic sulphonamides
WO2006030211A3 (en) * 2004-09-14 2006-06-01 Vernalis R&D Ltd Acyclic sulphonamides
EP2305652A2 (de) 2005-12-08 2011-04-06 Novartis AG Trisubstituierte Chinazolinonderivate als Vanilloidantagonisten
WO2007125398A2 (en) * 2006-04-27 2007-11-08 Pfizer Japan Inc. : sulfonamide compounds as antagonists of the n-type calcium channel
WO2007125398A3 (en) * 2006-04-27 2008-03-06 Pfizer Japan Inc : sulfonamide compounds as antagonists of the n-type calcium channel
JP2010504930A (ja) * 2006-09-29 2010-02-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換されたスルホンアミド誘導体
JP2010529020A (ja) * 2007-05-31 2010-08-26 塩野義製薬株式会社 オキシイミノ化合物およびその使用
US8324249B2 (en) 2008-08-01 2012-12-04 Purdue Pharma L.P. Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
WO2010084050A2 (en) 2009-01-13 2010-07-29 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2010091721A1 (en) * 2009-02-11 2010-08-19 Glaxo Group Limited 3 -substituted 1-arylsulfonylpiperidine derivatives for the treatment of pain
JP2012518038A (ja) * 2009-02-18 2012-08-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する複素環化合物
US8889670B2 (en) 2009-02-18 2014-11-18 Boehringer Ingelheim International Gmbh Heterocyclic compounds which modulate the CB2 receptor
WO2010096371A3 (en) * 2009-02-18 2010-11-11 Boehringer Ingelheim International Gmbh Heterocyclic compounds which modulate the cb2 receptor
CN102762534A (zh) * 2009-09-18 2012-10-31 扎里卡斯药品有限公司 作为钙通道阻断剂的芳基砜衍生物
EP2477963A1 (de) * 2009-09-18 2012-07-25 Zalicus Pharmaceuticals Ltd. Arylsulfonderivate als calciumkanalblocker
EP2477963A4 (de) * 2009-09-18 2013-02-27 Zalicus Pharmaceuticals Ltd Arylsulfonderivate als calciumkanalblocker
US9315454B2 (en) 2010-01-15 2016-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
WO2012164473A1 (en) 2011-05-27 2012-12-06 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
WO2013164790A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
US8865744B1 (en) 2013-05-17 2014-10-21 Boehringer Ingelheim International Gmbh (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US10112934B2 (en) 2013-05-17 2018-10-30 Centrexion Therapeutics Corporation (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US11725004B2 (en) 2013-05-17 2023-08-15 Centrexion Therapeutics Corporation (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US11084810B2 (en) 2013-05-17 2021-08-10 Centrexion Therapeutics Corporation (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US10570125B2 (en) 2013-05-17 2020-02-25 Centrexion Therapeutics Corporation (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US9650370B2 (en) 2013-05-17 2017-05-16 Centrexion Therapeutics Corporation (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN105732458A (zh) * 2014-12-29 2016-07-06 成都先导药物开发有限公司 吡咯酰胺类化合物及其制备方法与用途
JP2018503683A (ja) * 2014-12-29 2018-02-08 成都先導薬物開発有限公司 ピロールアミド系化合物、その製造方法、及び用途
US10266489B2 (en) 2014-12-29 2019-04-23 Hitgen Ltd Pyrrolic amide compound and preparation method and application thereof
CN105801464B (zh) * 2014-12-29 2019-05-28 成都先导药物开发有限公司 吡咯酰胺类化合物及其制备方法与用途
CN105732459B (zh) * 2014-12-29 2019-05-31 成都先导药物开发有限公司 吡咯酰胺类化合物及其制备方法与用途
CN105801464A (zh) * 2014-12-29 2016-07-27 成都先导药物开发有限公司 吡咯酰胺类化合物及其制备方法与用途
WO2016107227A1 (zh) * 2014-12-29 2016-07-07 成都先导药物开发有限公司 吡咯酰胺类化合物及其制备方法与用途
CN105732459A (zh) * 2014-12-29 2016-07-06 成都先导药物开发有限公司 吡咯酰胺类化合物及其制备方法与用途

Also Published As

Publication number Publication date
EP1664010A1 (de) 2006-06-07

Similar Documents

Publication Publication Date Title
WO2005068448A1 (en) Sulfonamides antagonising n-type calcium channels
JP6014154B2 (ja) ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
EP1882684B1 (de) Pyrrolidinderivat oder salz davon
US7652060B2 (en) Small molecule rotamase enzyme inhibitors
AU2002258414B2 (en) Acylated piperidine derivatives as melanocortin-4 receptor agonists
JP4812778B2 (ja) （１，５−ジフェニル−１ｈ−ピラゾール−３−イル）オキサジアゾール誘導体、この調製方法および治療剤におけるこの使用
US8153658B2 (en) Piperidine derivative or salt thereof
US7067529B2 (en) Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors
JP4602672B2 (ja) プロスタグランジンｆ受容体のモジュレーターとしてのチアゾリジンカルボキサミド誘導体
JP2006514102A (ja) ２−オキソ−エタンスルホンアミド誘導体
AU2009273105B2 (en) Azole compound
SK8762001A3 (en) Piperidines as CCR5 modulators
MX2011005954A (es) Compuesto de 2h-cromeno y su derivado.
JP2003519135A (ja) 環状ａｍｐ特異性ホスホジエステラーゼ阻害剤としてのピロリジン誘導体
AU2006250354A1 (en) Pyrazole compound and therapeutic agent for diabetes comprising the same
MX2007011694A (es) Derivados de pirrolidina 3,4-sustituida para el tratamiento de hipertension.
JP2007510702A (ja) 代謝性疾患の処置に有用な１１−β−ＨＳＤ１阻害剤としてのＮ−アシル化−３−（ベンゾイル）−ピロリジン
CN108289886A (zh) 离子通道抑制化合物、药物制剂和用途
WO2006030211A2 (en) Acyclic sulphonamides
EP2352730A2 (de) Biologisch aktive amide
EA007335B1 (ru) Новые соединения и композиции как ингибиторы катепсина
JP5258763B2 (ja) ５−フェニル−３−ピリダジノン誘導体
ES2397305T3 (es) Derivados de oxadiazol y tiadiazol-oxima de pirrolidina que son antagonistas del receptor oxitocina
US6291510B1 (en) Small molecule inhibitors of rotamase enzyme activity
RU2324694C2 (ru) Производные 2-пирролидин-2-ил-[1,3,4]оксадиазола и их применение в качестве антидепрессантов

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004768255

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004768255

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004768255

Country of ref document: EP